Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure

Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.

Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.

blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).

Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician

One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes